Conditions: Prostate Cancer
Allocation: NON_RANDOMIZED | Intervention model: SINGLE_GROUP
Enrollment: 42
Healthy volunteers: no

Brief summary:
The purpose of this study is to evaluate safety and efficacy of Omnitarg (Pertuzumab) on cancerous lesions in men with castration-resistant (hormone-refractory) prostate cancer.

Detailed description:

Arms:

Interventions: intervention 1: rhuMAb 2C4 (pertuzumab)
Intervention descriptions: intervention 1: None

Protocol document: